The paracaspase MALT1 mediates CARD14-induced signaling in keratinocytes

EMBO Reports

Volumn 17, Issue 6, 2016, Pages 914-927

  Afonina, Inna S ^a,b   Van Nuffel, Elien ^a,b   Baudelet, Griet ^a,b   Driege, Yasmine ^a,b   Kreike, Marja ^a,b   Staal, Jens ^a,b   Beyaert, Rudi ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

CARD14 signaling pathway; inflammation; MALT1; proteolytic activity; psoriasis

Indexed keywords

CASPASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRO ALPHA PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PARACASPASE MALT1; PROTEIN BCL 10; RANTES; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CARD14 PROTEIN, HUMAN; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; CYTOKINE; GUANYLATE CYCLASE; MALT1 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN BINDING; TUMOR PROTEIN;

ARTICLE; B LYMPHOCYTE; CARD14 GENE; COMPLEX FORMATION; CONTROLLED STUDY; GENE; GENE EXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PSORIASIS; REPORTER GENE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; CATALYSIS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION;

BIOMARKERS; CARD SIGNALING ADAPTOR PROTEINS; CASPASES; CATALYSIS; CYTOKINES; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GUANYLATE CYCLASE; HUMANS; KERATINOCYTES; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MUTATION; NEOPLASM PROTEINS; NF-KAPPA B; PROTEIN BINDING; PSORIASIS; SIGNAL TRANSDUCTION;

EID: 84964226747     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.15252/embr.201642109     Document Type: Article

References (45)

1. Lowes MA, Suarez-Farinas M, Krueger JG, (2014) Immunology of psoriasis. Annu Rev Immunol 32: 227-255
2. Albanesi C, De Pita O, Girolomoni G, (2007) Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol 25: 581-588
3. Jordan CT, Cao L, Roberson ED, Duan S, Helms CA, Nair RP, Duffin KC, Stuart PE, Goldgar D, Hayashi G, et al, (2012) Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet 90: 796-808
4. Jordan CT, Cao L, Roberson ED, Pierson KC, Yang CF, Joyce CE, Ryan C, Duan S, Helms CA, Liu Y, et al, (2012) PSORS2 is due to mutations in CARD14. Am J Hum Genet 90: 784-795
5. Fuchs-Telem D, Sarig O, van Steensel MA, Isakov O, Israeli S, Nousbeck J, Richard K, Winnepenninckx V, Vernooij M, Shomron N, et al, (2012) Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet 91: 163-170
6. Berki DM, Liu L, Choon SE, David Burden A, Griffiths CE, Navarini AA, Tan ES, Irvine AD, Ranki A, Ogo T, et al, (2015) Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris. J Invest Dermatol 135: 2964-2970
7. Blonska M, Lin X, (2011) NF-kappaB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res 21: 55-70
8. Scudiero I, Vito P, Stilo R, (2014) The three CARMA sisters: so different, so similar: a portrait of the three CARMA proteins and their involvement in human disorders. J Cell Physiol 229: 990-997
9. Hulpiau P, Driege Y, Staal J, Beyaert R, (2016) MALT1 is not alone after all: identification of novel paracaspases. Cell Mol Life Sci 73: 1103-1116
10. Demeyer A, Staal J, Beyaert R, (2016) Targeting MALT1 proteolytic activity in immunity, inflammation and disease: good or bad? Trends Mol Med 22: 135-150
11. Hailfinger S, Lenz G, Thome M, (2014) Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspase. Curr Opin Chem Biol 23C: 47-55
12. Scudiero I, Zotti T, Ferravante A, Vessichelli M, Vito P, Stilo R, (2011) Alternative splicing of CARMA2/CARD14 transcripts generates protein variants with differential effect on NF-kappaB activation and endoplasmic reticulum stress-induced cell death. J Cell Physiol 226: 3121-3131
13. Bertin J, Wang L, Guo Y, Jacobson MD, Poyet JL, Srinivasula SM, Merriam S, DiStefano PS, Alnemri ES, (2001) CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. J Biol Chem 276: 11877-11882
14. Johansen C, Kragballe K, Westergaard M, Henningsen J, Kristiansen K, Iversen L, (2005) The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 152: 37-42
15. Takahashi H, Ibe M, Nakamura S, Ishida-Yamamoto A, Hashimoto Y, Iizuka H, (2002) Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. J Dermatol Sci 30: 94-99
16. Ip YT, Davis RJ, (1998) Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr Opin Cell Biol 10: 205-219
17. Gross O, Gewies A, Finger K, Schafer M, Sparwasser T, Peschel C, Forster I, Ruland J, (2006) Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 442: 651-656
18. Bertin J, Guo Y, Wang L, Srinivasula SM, Jacobson MD, Poyet JL, Merriam S, Du MQ, Dyer MJ, Robison KE, et al, (2000) CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B. J Biol Chem 275: 41082-41086
19. Baens M, Bonsignore L, Somers R, Vanderheydt C, Weeks SD, Gunnarsson J, Nilsson E, Roth RG, Thome M, Marynen P, (2014) MALT1 auto-proteolysis is essential for NF-kappaB-dependent gene transcription in activated lymphocytes. PLoS ONE 9: e103774
20. Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, Sun L, Chen ZJ, Marynen P, Beyaert R, (2008) T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 9: 263-271
21. Staal J, Driege Y, Bekaert T, Demeyer A, Muyllaert D, Van Damme P, Gevaert K, Beyaert R, (2011) T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J 30: 1742-1752
22. Jeltsch KM, Hu D, Brenner S, Zoller J, Heinz GA, Nagel D, Vogel KU, Rehage N, Warth SC, Edelmann SL, et al, (2014) Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(H)17 differentiation. Nat Immunol 15: 1079-1089
23. Uehata T, Iwasaki H, Vandenbon A, Matsushita K, Hernandez-Cuellar E, Kuniyoshi K, Satoh T, Mino T, Suzuki Y, Standley DM, et al, (2013) Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation. Cell 153: 1036-1049
24. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, et al, (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41: 199-204
25. Tejasvi T, Stuart PE, Chandran V, Voorhees JJ, Gladman DD, Rahman P, Elder JT, Nair RP, (2012) TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 132: 593-600
26. Oudot T, Lesueur F, Guedj M, de Cid R, McGinn S, Heath S, Foglio M, Prum B, Lathrop M, Prud'homme JF, et al, (2009) An association study of 22 candidate genes in psoriasis families reveals shared genetic factors with other autoimmune and skin disorders. J Invest Dermatol 129: 2637-2645
27. Nititham J, Taylor KE, Gupta R, Chen H, Ahn R, Liu J, Seielstad M, Ma A, Bowcock AM, Criswell LA, et al, (2015) Meta-analysis of the TNFAIP3 region in psoriasis reveals a risk haplotype that is distinct from other autoimmune diseases. Genes Immun 16: 120-126
28. Verstrepen L, Carpentier I, Verhelst K, Beyaert R, (2009) ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling. Biochem Pharmacol 78: 105-114
29. Sun SC, (2010) CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 17: 25-34
30. Catrysse L, Vereecke L, Beyaert R, van Loo G, (2014) A20 in inflammation and autoimmunity. Trends Immunol 35: 22-31
31. De A, Dainichi T, Rathinam CV, Ghosh S, (2014) The deubiquitinase activity of A20 is dispensable for NF-kappaB signaling. EMBO Rep 15: 775-783
32. Verhelst K, Carpentier I, Kreike M, Meloni L, Verstrepen L, Kensche T, Dikic I, Beyaert R, (2012) A20 inhibits LUBAC-mediated NF-kappaB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J 31: 3845-3855
33. Fukuoka M, Ogino Y, Sato H, Ohta T, Komoriya K, Nishioka K, Katayama I, (1998) RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol). Br J Dermatol 138: 63-70
34. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles KE, Tian S, Cardinale I, Chimenti S, Krueger JG, (2011) Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 131: 677-687
35. Hara H, Wada T, Bakal C, Kozieradzki I, Suzuki S, Suzuki N, Nghiem M, Griffiths EK, Krawczyk C, Bauer B, et al, (2003) The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity 18: 763-775
36. Gonzalez-Mariscal L, Betanzos A, Avila-Flores A, (2000) MAGUK proteins: structure and role in the tight junction. Semin Cell Dev Biol 11: 315-324
37. Hailfinger S, Nogai H, Pelzer C, Jaworski M, Cabalzar K, Charton JE, Guzzardi M, Decaillet C, Grau M, Dorken B, et al, (2011) Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc Natl Acad Sci USA 108: 14596-14601
38. Mc Guire C, Elton L, Wieghofer P, Staal J, Voet S, Demeyer A, Nagel D, Krappmann D, Prinz M, Beyaert R, et al, (2014) Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis. J Neuroinflammation 11: 124
39. Nagel D, Spranger S, Vincendeau M, Grau M, Raffegerst S, Kloo B, Hlahla D, Neuenschwander M, Peter von Kries J, Hadian K, et al, (2012) Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 22: 825-837
40. Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SN, et al, (2012) MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 22: 812-824
41. Schmitt A, Grondona P, Maier T, Brandle M, Schonfeld C, Jager G, Kosnopfel C, Eberle FC, Schittek B, Schulze-Osthoff K, et al, (2016) MALT1 protease activity controls the expression of inflammatory genes in keratinocytes upon zymosan stimulation. J Invest Dermatol 136: 788-797
42. Gewies A, Gorka O, Bergmann H, Pechloff K, Petermann F, Jeltsch KM, Rudelius M, Kriegsmann M, Weichert W, Horsch M, et al, (2014) Uncoupling malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation. Cell Rep 9: 1292-1305
43. Jaworski M, Marsland BJ, Gehrig J, Held W, Favre S, Luther SA, Perroud M, Golshayan D, Gaide O, Thome M, (2014) Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity. EMBO J 33: 2765-2781
44. Bornancin F, Renner F, Touil R, Sic H, Kolb Y, Touil-Allaoui I, Rush JS, Smith PA, Bigaud M, Junker-Walker U, et al, (2015) Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation. J Immunol 194: 3723-3734
45. Yu JW, Hoffman S, Beal AM, Dykon A, Ringenberg MA, Hughes AC, Dare L, Anderson AD, Finger J, Kasparcova V, et al, (2015) MALT1 protease activity is required for innate and adaptive immune responses. PLoS ONE 10: e0127083